Answer reasoning questions

2f936f80-a5bf-4a1d-aef8-9fcdba66efd5.jpeg

Reading File

Finding Sources

Here are detailed answers to all 9 reasoning questions:

REASONING TYPE QUESTIONS - ANSWERS

1. Cotrimoxazole is especially valuable for chronic/recurrent UTIs or in prostatitis.

Reason: Cotrimoxazole (trimethoprim + sulfamethoxazole) works by a sequential double blockade of the folate synthesis pathway - sulfamethoxazole inhibits dihydropteroate synthase, and trimethoprim inhibits dihydrofolate reductase. This synergistic combination is bactericidal (not merely bacteriostatic), which is essential for eradicating bacteria in difficult-to-treat sites. For prostatitis, trimethoprim has excellent lipid solubility and penetrates the blood-prostate barrier very effectively, achieving therapeutic concentrations in prostatic tissue and fluid. For chronic/recurrent UTIs, the bactericidal action ensures sterilization of the urinary tract and prevents relapse, unlike drugs that are merely bacteriostatic.

2. Ciprofloxacin should not be used as the primary drug in respiratory infections.

Reason: Ciprofloxacin is a second-generation fluoroquinolone with poor activity against Gram-positive organisms, especially Streptococcus pneumoniae (pneumococcus), which is the most common cause of community-acquired pneumonia (CAP) and many respiratory tract infections. Its minimum inhibitory concentration (MIC) against S. pneumoniae is high, making it clinically unreliable. Newer "respiratory fluoroquinolones" like levofloxacin and moxifloxacin have much better Gram-positive and atypical organism coverage and are the preferred fluoroquinolones for respiratory infections. Using ciprofloxacin as the primary agent risks treatment failure.

3. Norfloxacin is used for bactericidal diarrhoeas.

Reason: Norfloxacin is a first-generation fluoroquinolone that concentrates very highly in the gastrointestinal tract and urine, but achieves poor systemic blood levels (low bioavailability compared to later quinolones). Since bacterial diarrhoeas (e.g., caused by Shigella, E. coli, Salmonella, Campylobacter) are infections localised to the gut lumen and intestinal mucosa, norfloxacin's high intraluminal concentrations are ideal. It exerts a rapid bactericidal action by inhibiting bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, preventing DNA replication, transcription, and repair. Its poor systemic absorption also means fewer systemic side effects while still achieving effective local concentrations.

4. Moxifloxacin should not be given in patients on proarrhythmic drugs.

Reason: Moxifloxacin causes QT interval prolongation on the ECG by blocking cardiac hERG potassium channels (I_Kr), which are responsible for rapid cardiac repolarisation. Prolongation of the QT interval predisposes to a potentially fatal ventricular arrhythmia called Torsades de Pointes (TdP). If moxifloxacin is combined with other drugs that also prolong the QT interval (proarrhythmic drugs) - such as class IA antiarrhythmics (quinidine, procainamide), class III antiarrhythmics (amiodarone, sotalol), tricyclic antidepressants, antipsychotics, or macrolides - there is an additive/synergistic QT prolongation, dramatically increasing the risk of TdP and sudden cardiac death. This combination is therefore contraindicated. Among fluoroquinolones, moxifloxacin carries the highest risk of QT prolongation.

5. Sulfonamides are ineffective against host cells.

Reason: Sulfonamides are structural analogues of para-aminobenzoic acid (PABA) and work by competitively inhibiting the enzyme dihydropteroate synthase, blocking bacterial folate synthesis. This mechanism is selective for bacteria because:

Bacteria must synthesise their own folate from PABA - they cannot take up preformed folate from the environment.
Human/host cells cannot synthesise folate at all - they lack the enzyme dihydropteroate synthase entirely. Instead, they rely entirely on preformed folate obtained from the diet.

Since the drug's target enzyme does not exist in human cells, sulfonamides cannot affect host cell metabolism. This is also why sulfonamides do not affect viruses or other organisms that scavenge preformed folate.

6. Silver sulfadiazine is preferred for burns.

Reason: Silver sulfadiazine (1% cream) combines two antimicrobial agents - silver ions and sulfadiazine - which act synergistically against a broad spectrum of organisms including Pseudomonas aeruginosa, Staphylococcus aureus, E. coli, and many other pathogens commonly colonising burn wounds. Key advantages:

Burns are highly susceptible to infection due to loss of skin barrier, moist eschar, and necrotic tissue.
Silver ions act on bacterial cell walls and membranes and denature bacterial DNA.
Silver sulfadiazine has low systemic absorption, minimising systemic toxicity.
It is easy to apply, painless, and provides sustained slow release of silver.
It covers Pseudomonas, which is a major threat in burn infections and is resistant to many antibiotics.

7. Diuretics should not be combined with cotrimoxazole in elderly patients.

Reason: Thiazide diuretics and cotrimoxazole both increase the risk of thrombocytopenia (low platelet count), and this risk is significantly amplified when combined, especially in the elderly who already have reduced bone marrow reserve. Additionally:

Both drugs can cause folate deficiency - cotrimoxazole inhibits folate metabolism (trimethoprim inhibits DHFR), and elderly patients are often already folate-depleted.
The combination increases the risk of megaloblastic anaemia and pancytopenia.
Trimethoprim also blocks tubular secretion of creatinine and can cause hyperkalaemia (it blocks epithelial sodium channels in the distal nephron similar to amiloride). Combined with potassium-sparing diuretics, this risk is even greater.
Elderly patients have reduced renal clearance, increasing drug accumulation and toxicity.

8. Fluoroquinolones (quinolones) are contraindicated in children.

Reason: Studies in juvenile animals (puppies, rat pups) given fluoroquinolones showed damage to developing articular cartilage - specifically erosion of the weight-bearing cartilage in large joints, leading to arthropathy, effusion, and lameness. The mechanism involves:

Fluoroquinolones chelate magnesium ions (Mg²⁺), which are essential for cartilage matrix integrity and chondrocyte function.
Depletion of Mg²⁺ in developing cartilage causes chondrocyte toxicity and matrix degradation.
Growing children have active cartilage growth plates (epiphyseal plates), making them especially vulnerable.

Since this arthropathy has been documented in animal models, fluoroquinolones are generally contraindicated in children under 18 years and in pregnant women (fetal cartilage). Exceptions exist (e.g., ciprofloxacin for inhalation anthrax, certain Pseudomonas infections in cystic fibrosis) where benefit outweighs risk.

9. NSAIDs and theophylline should not be combined with fluoroquinolones.

Reason: Two separate but important interactions:

NSAIDs + Fluoroquinolones: Both NSAIDs and fluoroquinolones inhibit GABA (gamma-aminobutyric acid) binding in the CNS. Fluoroquinolones weakly block GABA-A receptors; NSAIDs potentiate this effect. The combination dramatically lowers the seizure threshold, significantly increasing the risk of CNS toxicity and convulsions/seizures. This is particularly dangerous in patients with pre-existing epilepsy or CNS disorders.

Theophylline + Fluoroquinolones: Ciprofloxacin (and some other fluoroquinolones) inhibit hepatic cytochrome P450 enzymes (specifically CYP1A2), which are the primary enzymes responsible for metabolising theophylline. Inhibition of CYP1A2 reduces theophylline clearance, leading to elevated plasma theophylline levels - theophylline has a narrow therapeutic index, so even modest increases can cause theophylline toxicity: nausea, vomiting, palpitations, arrhythmias, and seizures. The theophylline dose must be reduced (by ~30-50%) if ciprofloxacin is co-prescribed.

This is a shared conversation. Sign in to Orris to start your own chat.